Novel targeted therapy and immunotherapy drugs have recently been approved for use in patients with surgically resectable lung cancer. Accurate staging, early molecular testing, and knowledge of recent trials are critical to optimize oncologic outcomes in these patients.
Keywords: adjuvant; clinical staging; immunotherapy; neoadjuvant; non–small cell lung cancer; surgery; targeted therapy.
Copyright © 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.